AbbVie (NYSE: ABBV) announces that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. Capstan’s lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies.
Read the full article: AbbVie Completes Acquisition of Capstan Therapeutics //
Source: https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-capstan-therapeutics-302533462.html